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Research Sequential biventricular pacing improves regional 
contractility, longitudinal function and 
dyssynchrony in patients with heart failure and 
prolonged QRS
Magnus Edner*1, Margareta Ring1,2 and Tooomas Särev1
Abstract
Aims: Biventricular pacing (BiP) is an effective treatment in systolic heart failure (HF) patients with prolonged QRS. 
However, approximately 35% of the patients receiving BiP are classified as non-responders. The aim of this study is to 
evaluate the acute effects of VV-optimization on systolic heart function.
Methods: Twenty-one HF patients aged 72 (46-88) years, QRS 154 (120-190) ms, were studied with echocardiography, 
Tissue Doppler Imaging (TDI) and 3D-echo the first day after receiving a BiP device. TDI was performed; during 
simultaneous pacing (LV-lead pacing 4 ms before the RV-lead) and during sequential pacing (LV 20 and 40 ms before 
RV and RV 20 and 40 ms before LV-lead pacing). Systolic heart function was studied by tissue tracking (TT) for 
longitudinal function and systolic maximal velocity (SMV) for regional contractility and signs of dyssynchrony assessed 
by time-delays standard deviation of aortic valve opening to SMV, AVO-SMV/SD and tissue synchronization imaging 
(TSI).
Results: The TT mean value preoperatively was 4,2 ± 1,5 and increased at simultaneous pacing to 5,0 ± 1,2 mm (p < 
0,05), and at best VV-interval to 5,4 ± 1,2 (p < 0,001). Simultaneous pacing achieved better TT distance compared with 
preoperative in 16 patients (76%). However, it was still higher after VV-optimization in 12 patients 57%. Corresponding 
figures for SMV were 3,0 ± 0,7, 3,5 ± 0,8 (p < 0,01), and 3,6 ± 0,8 (p < 0,001). Also dyssynchrony improved.
Conclusions: VV-optimization in the acute phase improves systolic heart function more than simultaneous BiP pacing. 
Long-term effects should be evaluated in prospective randomized trials.
Introduction
Chronic heart failure (CHF) is perhaps the most common
reason for in-hospital health care utilization and costs are
very high. Despite drugs such as RAAS-blockers, beta-
blockers, diuretics and aldosterone-antagonists which all
have positive prognostic effects these patients suffer from
poor quality of life (QoL) and a readmission rate as high
as 30% within 90 days [1-5].
Cardiac Resynchronization Therapy (CRT) is estab-
lished as an effective treatment in systolic heart failure
(HF) patients with prolonged QRS being in functional
class (NYHA) III-IV despite optimal medical treatment.
CRT has been shown to improve heart function, QoL,
morbidity and mortality [6-10]. However, approximately
30-40% of the patients receiving a CRT pacemaker do not
respond as expected. There are several possible explana-
tions to this such as non-viable myocardium, wrong indi-
cation, suboptimal LV lead location and one reason might
also be suboptimal programming of the CRT device.
When giving effective drugs as RAAS- and beta-block-
ers it is obvious that dosages should be individualized and
slowly optimized to achieve best effects and to avoid
adverse effects. In CRT, however, it seems uncommon to
individualize and optimize programming of the device
and there are so far surprisingly few long-term random-
ized studies on this issue. Patients with CHF in NYHA-
class III or IV have very high one- year mortality, 30-50%,
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which should make attempts to optimize the CRT device
high priority. In the land-mark study CARE-HF [10], AV-
delay was optimized, according to protocol, before dis-
charge, after 3 months and every 6 months thereafter.
This is today the recommendation by the American soci-
ety of echocardiography [11].
The aim of this study was to evaluate the effect of VV-
optimization during the first day after implantation of a
CRT device on systolic heart function and signs of dys-
synchrony.
Methods and patients
Study Population
We enrolled 21 consecutive heart failure patients with
standard criteria for biventricular pacemaker treatment.
All patients had reduced systolic left ventricular (LV)
function with an ejection fraction (EF) below 35%, QRS -
duration >120 ms and New York Heart Association
(NYHA) function class III-IV despite optimal medical
treatment. Twenty-one patients were on ACEi/ARB:s, 21
on diuretics and 19 were on beta blockers. Mean age was
72 (range 46-88) years and 18 patients were of male gen-
der (Table 1). Exclusion criteria were artrial fibrillation.
The study adhered to the Declaration of Helsinki and all
patients gave informed consent. The study was approved
by the Regional Ethical Review Board.
Echocardiography and Tissue Doppler Imaging
The patients were examined in the left lateral position
and Tissue Doppler Imaging (TDI) echocardiography was
acquired in three apical views using a vivid 7 or 5 (the
later for 3-D echocardiography only) system (Vingmed,
Hortem, Norway), with a 2.5 MHz probe. Three consecu-
tive beats were registered and mean values were used for
further analysis. Analyses were made off-line (Echo-Pac
software, Hortem, Norway). Systole was defined as the
ejection time from the aortic valve opening (AVO) to the
aortic valve closure (AVC). The 16 segments LV-model of
the American Society of Echocardiography was used for
orientation [12]. Base and mid LV-segments, total of 12,
were used together with base and mid RV-segments in
the 4-chamber view. The LV enddiastolic dimension
(LVEDd) was measured in the PLAX view from 2D regis-
trations at maximal diameter at the site below the mitral
valve. The LV endsystolic diameter (LVESd) was mea-
sured in the same view with the smallest achievable LV
size. Systolic functionas regional systolic contractility was
measured by SMV during the ejection phase in the same
segments. Tissue tracking (TT) was used to measure lon-
gitudinal function in each segment.
Dyssynchrony was measured by 2 different methods
AVO-SMV/SD (systolic maximal velocity) where the time
AVO-SMV max was calculated in ms for each of the 14
segments. A mean value with a standard deviation (SD)
was calculated, the SD given as a measure of dyssyn-
chrony. We also used Tissue Synchronization Imaging
(TSI). The TSI start was set at the AVO and the TSI end
at the AVC in order to focus only on the systolic phase. A
cut-off value of 65 ms was chosen prospectively. All the
TDI analysis were performed twice by the same investiga-
tor and the mean of the two measurements was used.
Intra-variability was fairly low. The coefficient of varia-
tion for TSI analysis was 3,0%.
Transthoracic 3D Echo was performed using a 2,5 MHz
transducer mounted in a handheld rotation device. The
cardiac images were recorded from the apex during end-
expiratory apnoea within one breath hold, whereby the
need for respiratory triggering was abolished. Imaging
was performed using tissue harmonic mode using coaxial
rotation from the apical position and ECG-triggered
recording where each R-wave initiated a 30° stepwise
rotation of the transducer. A total of six scanning planes
obtained by 30° stepwise rotation of the transducer cov-
ered the entire LV. To eliminate disturbances caused by
cardiac arrhytmias, only R-R intervals within 20% of the
mean were accepted. Ejection fraction was calculated by
the formula EDV-ESV/EDV × 100. Body surface area
(BSA) was used to calculate EDVi and ESVi of the LV. All
examinations were stored on magnetic optical discs for
later off-line analysis.
Table 1: Baseline characteristics of the patients (n = 21).
Variable HF patients
Age (years) 72 ± 11 (46-88)
Gender (male %) 90
Heart Rate, bpm 67 ± 18 (range 35-129)
QRS-width, ms 154 ± 21 (120-190)
Function Class, NYHA (n)
III 19
IV 2
Previous Myocardial 
Infarction
11
Hypertension 3
Cardiomyopathy 4
Diabetes 3
ACE/ARB 21
Diuretics 21
Beta-blockers 19
Spironolactone 15
Mean ± SD. HF= heart failure, NYHA = New York Heart 
Association, ACE = Angiotensin Converter Enzyme Inhibitor, ARB 
= Angiotensin Receptor Blocker.Edner et al. Cardiovascular Ultrasound 2010, 8:12
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Biventricular Pacemaker Implantation
All patients received a cardiac resynchronization therapy
(CRT) device (Insync III®, Medtronic) implanted trans-
venously with a lead in the right atrium and the RV lead
positioned in the middle of the ventricular septum. The
LV lead was positioned by identifying the sinus coronar-
ius in the right atrium and implanted in a lateral epicar-
dial vein in all patients except for three who had anterio-
lateral position of the LV lead. The latter location was
chosen due to anatomy in two patients and due to a high
threshold in the lateral position in one patient.
The day after implantation the patients were examined
with extensive Tissue Doppler Echocardiography (TDE).
TDE was performed after 10 minutes of pacing at each
VV- interval during simultaneous pacing LV lead (LV lead
4 ms before the RV lead and during sequential pacing (LV
20 and 40 ms before RV and RV 20 and 40 ms before LV
lead pacing). After this examination the atrium ventricu-
lar delay was optimized by using the longest achievable
(the iterative method) left ventricular filling time [13].
Statistical analysis
Mean values ± SD are given unless otherwise stated. For
within individual changes paired parametric student's t-
tests were used when variables showed normal distribu-
tion and non-parametric tests, Wilcoxon matched pairs,
when not. We used multiple linear regression to explain
the differences in LV-endsystolic diameter and in turn as
dependent variables age, gender, etiology, QRS-duration,
LV lead location, SMV, TT, AVO-SMV/SD and TSI were
used as possible predictors. Instead of using a step-wise
method for finding the best combination of predictors we
used the method of best subsets. The criterion used for
ranking those subsets was "Mallows Cp". A p value < 0.05
was considered statistically significant.
Results
Systolic function
Preoperative SMV was 3.0 ± 0.7 and at simultaneous pac-
ing it was 3.5 ± 0, 8 cm/sec (p < 0, 01)(+18 ± 17%). At best
VV-interval (sequential pacing) it increased to 3.6 ± 0,8 (p
< 0,0001) an increase of 23 ± 20% (range 0.5-70.1%)(Fig
1). Compared to preoperative values, SMV was higher in
16 patients at simultaneously pacing, unchanged in one
patient and lower in four patients. At the best VV-interval
17 patients had higher SMV and four patients unchanged
compared to preoperative SMV value. Fourteen patients
(66%) had higher SMV after VV-optimization compared
with simultaneous pacing (Fig 2). Best achievable VV-
interval was found with LV preactivated in 11 patients
(52%), RV preactivated in two and in the remaining at
simultaneous pacing (Fig 2).
Systolic function by the means of longitudinal shorten-
ing was measured by tissue tracking (TT) which preoper-
atively was 4.2 ± 1,5 mm and increased to 5.0 ± 1.2 mm (P
< 0.05)(+29 ± 47%) at simultaneous pacing. At the best
VV-interval it increased further to 5.4 ± 1.2 mm (p <
0.001) (+40 ± 53% with an individual range of -16-187%)
compared to preoperative values, TT was better in 16
patients at simultaneously pacing compared with preop-
erative value. Twelve patients (57%) had still higher TT
after VV-optimization compared with simultaneous pac-
ing (Fig 3). There was a correlation between changes in
SMV and TT (r = 0. 80, p < 0.001). However, highest SMV
and TT were reached at simultaneous pacing in 8 and 9
patients, respectively.
Dyssynchrony
Dyssynchrony measured by AVO-SMV/SD was preoper-
atively 40.9 ± 19.7 ms and at simultaneous pacing it
tended to increase, 42.9 ± 15.0 (n.s). However, at best VV-
interval it decreased to 35.0 ± 19.5 ms (P < 0,01) com-
pared with simultaneous pacing. Compared to preopera-
tive values, AVO-SMV/SD was better (lower) in 8
patients. Eighteen patients (86%) had less dyssynchrony
after VV-optimization compared with simultaneous pac-
ing (Fig 4).
Preoperative TSI showed dyssynchrony in 4.8 ± 2.8 seg-
ments and at simultaneous pacing in 5.9 ± 2.0 segments
(p = 0,10). After VV-optimization there were 3.6 ± 2.3
affected segments (p = 0,08 compared with baseline) and
statistically significantly less compared with simultane-
ous pacing (p < 0.001). Compared to preoperative values,
TSI was better in 8 patients at simultaneously pacing and
increased in 10 patients. At the best VV-interval, 16
patients (76%) had less dyssynchrony after VV-optimiza-
tion compared with simultaneous pacing (Fig 5). TSI cor-
related with dyssynchrony measured by AVO-SMV/SD
preoperatively and at best VV-interval, r = 0.48 p = 0.03
and r = 0.55 p = 0.01, respectively, but was not correlated
with SMV or TT at the best VV-interval.
All variables taken together optimal pacing was
a c h i e v e d  b y  s e q u e n t i a l  p a c i n g  i n  6 0 %  o f  t h e  p a t i e n t s .
Looking at sequential pacing, LV before RV was best in
75% and in this group LV 20 ms before RV was best in
60%.
Two years Follow-up
After two years 4 patients had died and 2 patients did not
agree to additional examination. Therefore reevaluation
of dimensions, volumes and EF could only be carried out
in 15 patients. However, LVEDd decreased 7.1 mm to
62.0 ± 8.3 mm (p < 0.05) and LVESd decreased 7.3 mm to
53.0 ± 9.5 mm (p < 0.05). LVEDVi and LVESVi decreased
27.1 and 27.6 ml respectively, however not statistically
significant. EF changed 4.8% to 30.8 ± 9.4%, n.s. Preoper-
ative values are given in Table 2.Edner et al. Cardiovascular Ultrasound 2010, 8:12
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A multiple linear regression analysis was performed to
see which variables explained the changes in LV dimen-
sions. Examined variables were age, gender, etiology,
QRS-duration, LV lead location, SMV, TT, AVO-SMV/
SD and TSI. The only variables explaining changes in LV
dimensions were SMV, AVO-SMV/SD and TSI.
Discussion
The main finding in this study is that approximately 2 of 3
patients with chronic heart failure (CHF) receiving car-
diac resynchronization therapy (CRT) improve their sys-
tolic heart function in the acute phase more with
sequential biventricular pacing than with simultaneous
biventricular pacing. This when systolic function is
expressed as regional contractility, longitudinal motion
and dyssynchrony measured by Tissue Doppler Imaging
echocardiography. Choosing sequential pacing, the best
choice in this study turned out to be pacing the LV lead
before the RV lead and of tested programming LV lead 20
ms before RV lead turned out to have best effect on sys-
tolic function.
Bearing the serious prognosis of these HF patients in
mind it should be obvious trying to get as much beneficial
effect as possible from the CRT device through individual
optimization. The highest individual increase in this
study was 187% of the TT value (sequential pacing) com-
pared with 75% at simultaneous pacing. Similar results
have been achieved by others [14].
An important question is whether to VV-optimize, AV-
delay optimize or to do both or to do neither.
I t ' s  d i f f i c u l t  t o  s a y  f o r  s u r e  w h a t  i s  r i g h t  s i n c e  t h e r e
today are too few long-term randomized controlled trials
(RCT's) to give a clear answer to this question. There are
mainly three types of dyssychrony which are to be treated
with CRT; inter-ventricular and intra-ventricular (both
affected by VV optimization) and atrio-ventricular
(affected by AV-delay optimization). The inter-ventricu-
lar mechanical delay (IVMD), is defined as the time dif-
ference between the onset of forward flow in the LV
outflow tract and RV outflow tract >40 ms and intra-ven-
tricular as when the time difference between regional
myocardial maximal velocities exceed 65 ms. Atrio-ven-
tricular dyssynchrony (LVFT/R-R) is considered present
if the left ventricular filling time (LVFT) measured from
the mitral valve Doppler in-flow signal is <40% of the car-
diac interval (R-R). The usual proportion of these differ-
ent types of dyssynchrony are 60%, 80% and 30% in such
HF patients with reduced ejection fraction and prolonged
QRS [15-18]. Moreover, the relationship between these
types of dyssynchrony is reported to be poor.
Figure 1 Tissue Doppler Imaging curves with systolic maximal velocity (SMV) preoperatively (left) and after implantation of CRT device 
(right), at best VV-interval (sequential pacing LV lead 40 ms before RV lead in this patient), showing improved systolic function, i.e. higher 
velocity. Signs of less dyssynchrony (arrows) are also seen.Edner et al. Cardiovascular Ultrasound 2010, 8:12
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Thus, the figures presented in this study strongly sug-
gest an individualized approach to optimization of the
CRT device since some patients might benefit from VV-
optimization, others from AV-delay optimization and
others from both. How reverse remodelling influences on
dyssynchrony and long-term effects of device optimiza-
tion should be studied in future RCT's. Two published
RCT's have however not demonstrated any beneficial
effects of VV optimization on LV dimensions, functional
class or QoL [19,20].
There are many ways to measure hemodynamik effects
of device programming.
Figure 3 The best VV-interval after optimization in each patient in this study (n = 21). With sequential pacing greatest longitudinal motion mea-
sured by tissue tracking (TT) was reached in 12 patients (57%).
Figure 2 The best VV-interval after optimization in each patient in this study (n = 21). With sequential pacing highest systolic maximal velocity 
(SMV) value was reached in 13 patients (62%).Edner et al. Cardiovascular Ultrasound 2010, 8:12
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Echocardiography measuring stroke volume by left
ventricular outflow tract (LVOT) VTI is perhaps most
used. We prefer the TDI method, since we are used to it
and therefore find it a time efficient method to find the
most appropriate programming with regard to it's rela-
tion with regional contractility (dP/dt) and longitudinal
function. This can also be achieved by visual examination
only, without the need for measurements (Fig 6). Thus, a
fast non-invasive method. Invasive dP/dt, blood pressure,
finger plethysmography, cardiac impedance, electrocar-
diogram and intracardiac electrogram (IEGM) are all use-
ful methods, at least in the acute phase, but they will
probably show slightly different results. Most important
Figure 4 The best VV-interval after optimization in each patient in this study (n = 21). With sequential pacing least dyssynchrony standard de-
viation of aortic valve opening to systolic maximal velocity (AVO-SMV/SD) was reached in 13 patients (62%).
Figure 5 The best VV-interval after optimization in each patient in this study (n = 21). With sequential pacing least dyssynchrony measured by 
Tissue Synchronization Imaging (TSI) was reached in 17 patients (81%).Edner et al. Cardiovascular Ultrasound 2010, 8:12
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is however, to use methods which one is accosted to and
relies on.
Study limitations
A major limitation of this study is the lack of randomiza-
tion and the small patient number. Designing this trial
again we would have included more patients and per-
formed a randomization to assess the long-term effects of
VV-optimization added onAV-delay optimization on LV
function, NYHA-class and QoL. However, we believe this
pilot study is important for highlighting the potential
individual effect of VV-optimization in HF patients with
prolonged QRS. Thus, even if this study is small and con-
tains no long-term data, VV-optimization the first day
after CRT implantation the study highlights the potential
benefits of such strategy.
The PROSPECT (Predictors of response to cardiac
resynchronization therapy) trial, an observational study,
was somewhat disappointing concerning the value of
measuring dyssynchrony [21]. This was a multicentre
study including 426 patients with standard indication for
CRT. The aim was to identify echocardiography and tis-
sue Doppler measures of dyssynchrony and their ability
to predict response to CRT. It was found that presence of
signs of dyssynchrony was linked to 11-13% additional
clinical response to CRT and 13-23% additional response
for reverse remodelling compared to absence of measures
of dyssynchrony. The main reason was a high inter-vari-
ability measuring signs of dyssynchrony. However, in a
recently published sub analysis of this trial dyssynchrony
was pointed out as one of the baseline characteristics to
benefit of biventricular pacing [22]. The most useful mea-
sures of dyssynchrony according to this analysis are inter-
ventricular (IVMD) and intra-ventricular (Ts lat-sept)
Figure 6 Tissue tracking (TT) preoperatively (left) and after implantation of CRT device (right), at best VV-interval (sequential pacing LV 
lead 20 ms before RV lead in this patient), showing improved systolic function, i.e. longitudinal motion. TT is a fast non-invasive method to 
study changes in systolic function fairly close related with changes in SMV (r = 0.80, p < 0.001).
Table 2: Echocardiography and Tissue Doppler before 
device implantation (n = 21).
Variable (range) Preoperative
Tissue Tracking, mm 4,2 ± 1,5 (2,2-6,9)
Systolic Maximal Velocity, 
cm/s
3,0 ± 0,7 (1,8-4,6)
AVO - SMV/SD, ms 40.9 ± 19.7 (19.7-107.2)
Tissue Synchronization 
Imaging, segments
4,8 ± 2,8 (0,9-8,0)
LVEDd, mm 69.1 ± 9.6 (54.8-88.7)
LVESd, mm 60,5 ± 11.2 (37,9-81,3)
EF, % 26,0 ± 7.5 (10,4-35,4)
LVEDVi, ml/m2 128,4 ± 51,6 (63,1-234,3)
LVESVi, ml/m2 100,2 ± 47,2 (57,3-202,0)
Mean ± SD. AVO Aortic Valve Opening, SMV = Systolic Maximal 
Velocity, LVEDd = left ventricular end diastolic diameter, LVESd = 
left ventricular end systolic diameter, EF = ejection fraction. EDVi 
= end diastolic volume index, ESVi = end systolic volume index.Edner et al. Cardiovascular Ultrasound 2010, 8:12
http://www.cardiovascularultrasound.com/content/8/1/12
Page 8 of 9
measures because these are the measures with lowest
inter-variability. The analysis also points out other impor-
tant baseline characteristics for being a responder to CRT
as female gender, non-ischemic ethiology, NYHA-class
III, QRS-duration and having no history of ventricular
tachycardia. These results show the difficulty of predict-
ing a responder and would rather support our hypothesis
that optimization of the device could be important during
the first months before the remodelling process takes
place.
Thus it is important to perform a solid echocardiogra-
phy examination not only to assess LV systolic function
and degree of dyssynchrony but also to avoid other causes
of heart failure, which shouldn't be treated with biventric-
ular pacing, as valve diseases and non-viable myocar-
dium. The latter can be done by a low-dose dobutamin
stress-echocardiography examination.
Conclusions
Approximately 2 of 3 patients with chronic heart failure
receiving cardiac resynchronization therapy improve
their systolic heart function in the acute phase more with
sequential biventricular pacing than with simultaneous
biventricular pacing. Choosing sequential pacing, the
best choice is to pace the LV lead before the RV lead and
of tested programming LV lead 20 ms before RV lead
turned out to have best effect on systolic function. The
long-term clinical importance of these findings should be
studied further.
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